The safety and therapeutic efficacy for application of biodegradable stent excel with biodegradble polymer combined with firofiban in patients with acute coronary syndrom
10.3760/cma.j.issn.1671-0282.2009.08.015
- VernacularTitle:国产替罗非班联合生物可降解支架Excel治疗急性冠脉综合征的安全性和疗效
- Author:
Yujuan ZHAO
;
Weimin LI
;
Lijun ZHOU
;
Shusen YANG
;
Pidong LIU
;
Yue LI
;
Yandong CHEN
;
Liyun SONG
;
Li SHENG
;
Bing FU
- Publication Type:Journal Article
- Keywords:
Drng-eluting stent;
Biodegradable stent;
Coronary artery disease;
Tirofiban;
Transluminal;
Percutaneous,angioplasty;
Acute coronary syndrom
- From:
Chinese Journal of Emergency Medicine
2009;18(8):835-840
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo evaluate the safety, and the brief-and prolongedterm therapeutic efficacy for im- plantation of biodegradable stent Excel combined with Tirofiban made in China into patients with acute coronary syndrome(ACS). MethodA total of 301 patients were divided into Excel group (n = 100), Cypher group (n =102) and bare metal stem(BMS) (n = 99). The Tirofiban used in three groups was administered intravenously during and after operation.The loading dose of Tirofiban was 10 μg/kg given within 3 min followed by a Tirofiban intravenous maintenance infusion in 0.15 μg/(kg·min) with micro pump for 48 hours. Safety and efficacy were compared among three groups after stents implantation by the observation of TIMI flow, complication of bleeding, changes of platelet count, haematoglobin and hematocrit, incidence of angina, acute and subacute thrombosis inner stent and major adverse cardiac events (MACE) (cardiac death, nonfatal myocardial infarction and target ves-sel revascularization). Follow-up information got from out-patient clinic and telephone call including incidence of angina, MACE and rehospitalization were comapared sucessively 1 month, 6 monthes and 12 monthes after dis- charge. ResultsAmong there groups,there were no significant differences in demographics,and physical and lab-oratory findings before treatment. Successful rate of implantation was 100 percent and the TIMI flow of class Ⅲ was found in all patients. There was no complication of stroke and massive hemorrhage of gastrointestinal tract, and no significant differences in complication of bleeding, platelet count, hemoglobin and hematocrit after implantation. Incidence rates of acute thrombosis were 0, 0.98 and 1.01 percent in three groups, and there was no significant difference in acute thrombosis inner stent among three groups (P >0.05). The rates of angina, sub.acute stent thrombosis, MACE and rehospitalization among three groups had no differences at 1 month and 6 monthes follow-up (P > 0.05), but significant differences were not found until 12 monthes follow-up (P < 0.05). Conclusions Drug-eluting stent Excel with biodegradable polymer combined with Tirofiban made in China implanted in patients with ACS were capable of preventing acute and later thrombosis inner stent. This procedure had favourable safety, and brief-term and proionge-term therapeutic efficacy.
